Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-08
2011-03-08
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S274000, C514S275000, C544S122000, C544S310000, C544S333000
Reexamination Certificate
active
07902192
ABSTRACT:
In general, the present invention relates to compounds capable of inhibiting p38, methods for inhibiting p38 in vivo or in vitro, and methods for treating conditions associated with p38 activity or cytokine activity.
REFERENCES:
patent: 3455924 (1969-07-01), Lednicer
patent: 4794114 (1988-12-01), Bender et al.
patent: 4892578 (1990-01-01), Chang et al.
patent: 5317019 (1994-05-01), Bender et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5777097 (1998-07-01), Lee et al.
patent: 5783664 (1998-07-01), Lee et al.
patent: 5869043 (1999-02-01), McDonnell et al.
patent: 5871934 (1999-02-01), Lee et al.
patent: 5955366 (1999-09-01), Lee et al.
patent: 5994412 (1999-11-01), Lee et al.
patent: 6033873 (2000-03-01), McDonnell et al.
patent: 6090626 (2000-07-01), Monia et al.
patent: 6162613 (2000-12-01), Su et al.
patent: 6187799 (2001-02-01), Wood et al.
patent: 6302838 (2001-10-01), O'Reilly et al.
patent: 6344476 (2002-02-01), Ranges et al.
patent: 6376214 (2002-04-01), Kumar et al.
patent: 6387641 (2002-05-01), Bellon et al.
patent: 6410518 (2002-06-01), Monia
patent: 6437147 (2002-08-01), Andersen et al.
patent: 6683100 (2004-01-01), van Hoogevest
patent: 6689883 (2004-02-01), Dumas et al.
patent: 6806258 (2004-10-01), Monia
patent: 6900221 (2005-05-01), Norris et al.
patent: 7449458 (2008-11-01), Bhamidipati et al.
patent: 7501430 (2009-03-01), Lapierre et al.
patent: 7528121 (2009-05-01), Heron et al.
patent: 2001/0006975 (2001-07-01), Wood et al.
patent: 2002/0042517 (2002-04-01), Uday et al.
patent: 2002/0058659 (2002-05-01), Andersen et al.
patent: 2002/0137774 (2002-09-01), Riedl et al.
patent: 2002/0165394 (2002-11-01), Dumas et al.
patent: 2003/0078432 (2003-04-01), Letavic et al.
patent: 2003/0125359 (2003-07-01), Lyons et al.
patent: 2003/0144278 (2003-07-01), Riedl et al.
patent: 2003/0181442 (2003-09-01), Riedl et al.
patent: 2003/0207872 (2003-11-01), Riedl et al.
patent: 2003/0207914 (2003-11-01), Dumas et al.
patent: 2003/0216396 (2003-11-01), Dumas et al.
patent: 2003/0216446 (2003-11-01), Dumas et al.
patent: 2004/0023961 (2004-02-01), Dumas et al.
patent: 2004/0087626 (2004-05-01), Renhowe et al.
patent: 2004/0122237 (2004-06-01), Amiri et al.
patent: 2006/0116357 (2006-06-01), Heron et al.
patent: 2007/0270384 (2007-11-01), Pittam et al.
patent: 2007/0270418 (2007-11-01), Ashwell et al.
patent: 2008/0032967 (2008-02-01), Ashwell et al.
patent: 2008/0045481 (2008-02-01), Sependa et al.
patent: 2009/0111985 (2009-04-01), Ashwell et al.
patent: 0 951 467 (2003-04-01), None
patent: 1 114 051 (2003-04-01), None
patent: 1 449 834 (2004-08-01), None
patent: 61214793 (1987-02-01), None
patent: WO 91/00092 (1991-01-01), None
patent: WO 95/03297 (1995-02-01), None
patent: WO 97/32604 (1997-09-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO 98/52559 (1998-11-01), None
patent: WO 99/20624 (1999-04-01), None
patent: WO 99/32106 (1999-07-01), None
patent: WO 99/32436 (1999-07-01), None
patent: WO 99/32455 (1999-07-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/42012 (2000-07-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 02/04447 (2002-01-01), None
patent: WO 02/062763 (2002-08-01), None
patent: WO 02/083628 (2002-10-01), None
patent: WO 02/085857 (2002-10-01), None
patent: WO 03/000682 (2003-01-01), None
patent: WO 03/033502 (2003-04-01), None
patent: WO 03/047523 (2003-06-01), None
patent: WO 03/047579 (2003-06-01), None
patent: WO 03/068223 (2003-08-01), None
patent: WO 03/068229 (2003-08-01), None
patent: WO 03/068746 (2003-08-01), None
patent: WO 03/087087 (2003-10-01), None
patent: WO 03/102139 (2003-12-01), None
patent: WO 2004/014870 (2004-02-01), None
patent: WO 2004/019941 (2004-03-01), None
patent: WO 2004/037789 (2004-05-01), None
patent: WO 2004/072025 (2004-08-01), None
patent: WO 2004/080464 (2004-09-01), None
patent: WO 2004/085399 (2004-10-01), None
patent: WO 2004/087905 (2004-10-01), None
patent: WO 2004/089929 (2004-10-01), None
patent: WO 2004/110990 (2004-12-01), None
patent: WO 2005/023761 (2005-03-01), None
patent: WO 2006/044869 (2006-04-01), None
patent: WO 2007/123892 (2007-11-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.
Bundgaard, Design of Prodrugs, p. 1, 1985.
Wolff, Some consideration for prodrug design, Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, vol. I: Principles and Practice, pp. 975-977, 1995.
Banker et al., Prodrugs, Modern Pharmaceutics, Third Edition, Revised and Expanded, pp. 451 and 596.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Douglas, Jr., Introduction of Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Ulrich, Chapter 4: Crystal Characteristics, Kirk Othmer Encyclopedia of Chemical Technology (7 pages), Aug. 2002.
Vippagunta et al., Crystalline Solids, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
West, Solid Solutions, Solid State Chemistry and its applications, pp. 358 & 365, 1988.
European Patent Office; Authorized Officer: Beyss-Kahana, E.,International Preliminary Report on Patentability and the Written Opinion of the International Searching Authority, International Application No. PCT/US2007/009348, dated Oct. 22, 2008, 9 pages.
Allen, et al., “CI-1040 (PD184352), A Targeted Signal Transduction Inhibitor of MEK(MAPKK),” Semin. Oncol. 30 (5 Suppl 16), pp. 105-116, 2003.
Davies, et al., “Mutations of the BRAF Gene in Human Cancer,” Nature, 417, pp. 949-954, 2002.
Hoeflich, et al., “Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models,” Cancer Res., 66(2), pp. 999-1006, 2006.
Li, et al., “Selective Killing of Cancer Cells by Beta-Lapachone: Direct Checkpoint Activation as a Strategy Against Cancer,” Proc. Natl. Acad. Sci. USA., 100(5), pp. 2674-2678, 2003.
Marais, et al., “Control of the ERK MAP Kinase Cascade by Ras and Raf,” Cancer Surv., 27, pp. 101-125, 1996.
Robinson, et al., “Mitogen-Activated Protein Kinase Pathways,” Curr. Opin. Cell Biol., 9, pp. 180-186, 1997.
Sharma, et al., “Mutant v599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors,” Cancer Res., 65(6), pp. 2412-2421, 2005.
Tuveson, et al., “BRAF as a Potential Therapeutic Target in Melanoma and Other Malignancies,” Cancer Cell, 4, pp. 95-98, 2003.
Wellbrock, et al., “v599E BRAF is an Oncogene in Melanocytes,” Cancer Res., 64, pp. 2338-2342, 2004.
Xing, “BRAF Mutation in Thyroid Cancer,” Endocrine-Related Cancer, 12, pp. 245-262, 2005.
OSI Pharmaceuticals, Inc. and Genetech, Inc., Full prescription information for Tarceva® erlotinib tablets, 4 pages, 2007.
Adams et al., “Pyrimidinylimidazole Inhibitors of CSBP/p38 Kinase Demonstrating Decreased Inhibition of Hepatic Cytochrome P450 Enzymes”Bioorg. Med. Chem. Lett., 8:3111-3116 (1998).
Adams et al., “Pyrimidinylimidazole Inhibitors of p38: Cyclic N-1 Imidazole Substituents Enhance p38 Kinase Inhibition and Oral Activity,”Bioorg. Med. Chem. Lett., 11:2867-2870 (2001).
Badger et al., “Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function,”J. Pharmacol. Exp. Ther., 279:1453-1461 (1996).
Bingham, “The Pathogenesis of Rheumatoid Arthritis: Pivotal Cytokines Involved in Degradation and Inflammation,”J. Rheumatol. Supp., 65:3-9 (2002).
Boehm et al., “New Inhibitors of p38 Kinase,”Expert Opinion on Therapeutic Patents, 10(1):25-37 (2000).
Bondeson et al., “Tumour Necrosis Factor as a Therapeutic Target in Rheumatoid Arthritis and other Chronic Inflammatory Diseases: The Clinical Experience with Infliximab (REMICADE),”Int. J. C
Ali Syed
Antonenko Valery
Ashwell Mark A.
Liu Jifeng
Liu Yanbin
ArQule, Inc.
Rao Deepak
Sunstein Kann Murphy & Timbers LLP
LandOfFree
Inhibitors of P38 and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of P38 and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of P38 and methods of using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2763668